KR20240163751A - Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 - Google Patents

Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240163751A
KR20240163751A KR1020247036173A KR20247036173A KR20240163751A KR 20240163751 A KR20240163751 A KR 20240163751A KR 1020247036173 A KR1020247036173 A KR 1020247036173A KR 20247036173 A KR20247036173 A KR 20247036173A KR 20240163751 A KR20240163751 A KR 20240163751A
Authority
KR
South Korea
Prior art keywords
seq
set forth
sequence set
bispecific antibody
nrp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036173A
Other languages
English (en)
Korean (ko)
Inventor
호준 송
Original Assignee
파인트리 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파인트리 테라퓨틱스 인코포레이티드 filed Critical 파인트리 테라퓨틱스 인코포레이티드
Publication of KR20240163751A publication Critical patent/KR20240163751A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020247036173A 2022-03-30 2023-03-30 Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 Pending KR20240163751A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325,312 2022-03-30
US63/325,317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240163751A true KR20240163751A (ko) 2024-11-19

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036173A Pending KR20240163751A (ko) 2022-03-30 2023-03-30 Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) * 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
CA3060190A1 (en) * 2017-04-24 2018-11-01 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Also Published As

Publication number Publication date
CL2024002899A1 (es) 2025-02-07
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
JP2025511135A (ja) 2025-04-15
EP4499696A1 (en) 2025-02-05
AU2023245728A1 (en) 2024-09-26
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CN119403831A (zh) 2025-02-07
CR20240462A (es) 2024-12-11
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
US20180009892A1 (en) Anti-ror1 antibodies
AU2015339306A1 (en) Combination therapy for cancer
US20190010232A1 (en) Checkpoint Inhibitor Bispecific Antibodies
AU2022206035B2 (en) Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
JP2021534094A (ja) 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物
KR20240144422A (ko) 암 치료의 단독치료법 및 병용치료법에서 il-18bp 길항제 항체 및 이의 용도
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
KR20240163751A (ko) Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법
US20240398943A1 (en) Methods of treating cancer and the pharmaceutical compositions thereof
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
EP4731256A1 (en) Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
JP2024509501A (ja) 新規活性を持つｈｈｌａ２結合剤
KR20250044738A (ko) 표적화 라이소좀 분해를 위한 조성물 및 이의 사용 방법
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
EA052797B1 (ru) Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения
KR20260051054A (ko) 표적화 라이소좀 분해를 위한 비-수용체 티로신 키나제 조성물 및 이의 이용 방법
TW202434631A (zh) 抗il-2抗體之使用方法
HK40113788A (zh) 抗cd39抗体及其用途
HK40019947A (en) Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000